ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "pulmonary"

  • Abstract Number: 0993 • ACR Convergence 2024

    Pulmonary Complications and Mortality Trends in Rheumatoid Arthritis Patients Aged 65 and Older in the United States: A CDC WONDER Database Analysis

    Muhammad Naveed1, Rabia Iqbal1, Kishan Patel2, Ahila Ali1, Simran Bhimani3, Bazil Azeem4, Yash Deshpande3, Muhammad Omer Rehan1, Faizan Ahmed5, Hussain Haider Shah1 and Nouman Shafique6, 1Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan, 2Riverside Community Hospital, Riverside, CA, 3The Wright Center for graduate medical education, Scranton, PA, 4Shaheed Mohtarma Benazir Bhutto Medical College Liyari, Karachi, Pakistan, 5Ameer-ud-Din Medical College, Lahore, Pakistan, 6AdventHealth Orlando, Orlando, FL

    Background/Purpose: Pulmonary complications in rheumatoid arthritis (RA) are an important cause of mortality among older adults. This study analyzes trends and demographic disparities in mortality…
  • Abstract Number: 2034 • ACR Convergence 2024

    Effectiveness and Tolerability of Tocilizumab in Systemic Autoimmune Rheumatic Disease Associated Intertistial Lung Disease

    Anne Dupont1, Clairelyne Dupin2, Esther Ebstein1, Marine Forien1, Sébastien Ottaviani1, Pierre Le Guen2, Quentin Philippot2, Raphaël Borie2, Bruno Crestani3, Philippe Dieudé1 and Pierre-Antoine Juge4, 1Departement of Rheumatology, AP-HP, Bichat Hospital, Paris, France, 2National Reference Center for Rare Pulmonary Diseases, Department of Pulmonology, AP-HP, Bichat Hospital, Paris, France, 3National Reference Center for Rare Pulmonary Diseases, Department of Pulmonology, AP-HP, Bichat Hospital, Paris, Ile-de-France, France, 4Departement of Rheumatology, AP-HP, Bichat Hospital, Boston, MA

    Background/Purpose: Interstitial lung diseases (ILD) are severe manifestations of systemic autoimmune diseases (SARD) that are associated with an increased mortality. Although the primary endpoint was not…
  • Abstract Number: 0263 • ACR Convergence 2024

    Characteristics and Coinfections of Diffuse Alveolar Hemorrhage in Rheumatic Patients

    Eduardo Briones-García1, Shaul Navarro-Lara2, Marco A Ortiz-Bustamante2, Iris Paola García Herrera3, Carla M Roman-Montes2 and Guillermo A Guaracha-Basañez4, 1Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department., Ciudad de México, Distrito Federal, Mexico, 2Departamento de Infectología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador-Zubirán., México city, Mexico, 3Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 4Instituto Nacional de Ciencias Medicas y Nutricion “Salvador Zubirán”, Mexico City, Distrito Federal, Mexico

    Background/Purpose: Diffuse alveolar hemorrhage (DAH) is a severe respiratory complication observed in certain rheumatic diseases, such as systemic lupus erythematosus (SLE), ANCA-associated vasculitides (AAV), and…
  • Abstract Number: 1070 • ACR Convergence 2024

    Evaluating & Improving Adherence to Pulmonary Hypertension Screening in Systemic Sclerosis Patients

    John Hickernell1 and Zineb Aouhab2, 1Loyola Univeristy Medical Center, Chicago, IL, 2Loyola University Medical Center, Oak Brook, IL

    Background/Purpose: Annual screening for pulmonary hypertension (PH) in patients with Systemic Sclerosis (SSc) has been shown to decrease mortality. The American College of Radiology, European…
  • Abstract Number: 2042 • ACR Convergence 2024

    Overview of Lung Manifestations in Sarcoidosis and Various Treatment Approaches at a University Center

    Aleeza Qamar1, Upasana Agrawal2, Karan Sachdeva3, Zara Hassan4, Alex Zamora1, Syeda Nida5, Sarwat Umer1, Samina Hayat1 and Kinza Muzaffar6, 1LSU Health-Shreveport, Shreveport, 2LSU Health, Shreveport, Shreveport, LA, 3Louisiana state university health shreveport LA, Shreveport, 4Louisiana State University Health Sciences, Shreveport, LA, 5LSU Healh-Shreveport, Shreveport, 6LSU HEALTH SHREVEPORT, SHREVEPORT, LA

    Background/Purpose: Sarcoidosis is a disease occurring in the form of non-caseating granulomas, with unclear etiology and multi-system manifestations. Pulmonary involvement in sarcoidosis is a cardinal…
  • Abstract Number: 0288 • ACR Convergence 2024

    Hypersensitivity Pneumonitis with Autoimmune Features: A New Entity?

    Pol Maymó1, Javier Narvaez-García2, Guadalupe Bermudo1, Vanesa Vicens-Zygmunt3, Santiago Bolivar4, Belen del Río5, Judith Palacios5, Martí Aguilar Coll2, Monserrat Roig Kim2, Laia De Daniel2, Paola Vidal1, Joan Miquel Nolla2 and María Molina1, 1Hospital Universtiario de Bellvitge, Barcelona, Spain, 2Hospital Universitario de Bellvitge, Barcelona, Spain, 3Hospital Universitario de Bellvitge., Barcelona, Spain, 4Bellvitge University Hospital, L'Hospitalet de Llobregat, Catalonia, Spain, 5Hospital Universtiario de Bellvitge, Hosptalet de Llobregat, Catalonia, Spain

    Background/Purpose: Hypersensitivity pneumonitis (HP) is an interstitial lung disease induced by inhaled antigens that trigger an interstitial and bronchoalveolar lymphocytic inflammatory response. This immune response…
  • Abstract Number: 1112 • ACR Convergence 2024

    Pleuroparenchymal Fibroelastosis Associated with Connective Tissue Diseases (PPFE-CTD)

    Maximiliano Diaz Menindez1, Alejandro Diaz Arumir Vergara2, Vivian Shing2, carolyn mead harvey3, Ana Zamora Martinez2 and Vivek Nagaraja4, 1Mayo Clinic School of Graduate Medical Education, Phoenix, AZ, 2Mayo Clinic, Phoenix, 3Mayo Clinic Florida, Jacksonville, FL, 4Mayo Clinic Arizona, Scottsdale, AZ

    Background/Purpose: Pleuroparenchymal Fibroelastosis (PPFE) is a rare idiopathic interstitial pneumonia characterized by fibrosis of the visceral pleura and subpleural parenchyma, predominantly affecting the upper lobes.…
  • Abstract Number: 2058 • ACR Convergence 2024

    Association of Anti-Synthetase Antibody Subtypes with Radiographic Progression of Interstitial Lung Disease in Anti-Synthetase Syndrome: An Analysis of the CLASS Project Database

    Daphne Rivero Gallegos1, Francisca Bozan2, Sangmee Bae3, Giovanni Zanframundo4, Sara Faghihi-Kashani5, Iazsmin Bauer Ventura6, Eduardo Dourado7, Gianluca sambataro8, Akira Yoshida9, Tamera J Corte10, Francesco Bonella11, Tracy J Doyle12, david fiorentino13, Miguel Angel Gonzalez-Gay14, marie Hudson15, Masataka Kuwana16, Antonella Notarnicola17, Andrew Mammen18, Neil McHugh19, Frederick Miller20, Carlomaurizio Montecucco21, Chester Oddis22, Jorge Rojas-Serrano23, Jens Schmidt24, Carlo A. Scire25, Albert Selva-O’Callaghan26, Victoria Werth27, Rohit Aggarwal28 and Lorenzo Cavagna29, and CLASS project participating investigators, 1INER, Ciudad de México, Mexico State, Mexico, 2Hospital Clinico Universidad de Chile, Santiago, Chile, 3UCLA, Los Angeles, CA, 4Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Milano, Italy, 5Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, San Francisco, CA, 6University of Chicago, Chicago, IL, 7Unidade Local de Saúde da Região de Aveiro, Aveiro, Portugal, 8University of Catania, Catania, Italy, 9Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan, 10Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia, 11Center for interstitial and rare lung diseases, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany, 12Brigham and Women's Hospital, West Roxbury, MA, 13Department of Dermatology, Stanford University School of Medicine, Stanford, CA, Palo Alto, CA, 14University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, 15McGill University, Montreal, QC, Canada, 16Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, 17Karolinska University Hospital and Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, 18NIH, Bethesda, MD, 19University of Bath, Bath, United Kingdom, 20NIH, NIEHS, Chapel Hill, NC, 21IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, 22Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 23National Institute of Respiratory Diseases, Ismael Cosío Villegas, Mexico City, Mexico, 24University Medical Center Goettingen, Göttingen, Germany, 25University of Milano Bicocca, Milan, Italy, 26Systemic Autoimmune Disease Unit, Vall d’Hebron Institute of Research, Barcelona, Spain, 27University of Pennsylvania, Wynnewood, PA, 28Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, 29University of Pavia and Fondazione IRCCS Policlinico San Matteo Hospital of Pavia, Pavia, Pavia, Italy

    Background/Purpose: In anti-synthetase syndrome (ASSD), clinical presentations vary from isolated interstitial lung disease (ILD) to systemic multi-organ manifestations. Several studies emphasize the crucial role of…
  • Abstract Number: 0299 • ACR Convergence 2024

    Real-World Tolerability of Nintedanib in Connective Tissue Disease-Associated Interstitial Lung Disease

    Saloni Goyal, Briana DiSilvio and Joanna Marco, Allegheny Health Network, Pittsburgh, PA

    Background/Purpose: Nintedanib is an antifibrotic medication used to treat interstitial lung disease (ILD), including connective tissue disease-associated ILD (CTD-ILD). Clinical trials that led to its…
  • Abstract Number: 1114 • ACR Convergence 2024

    Nintedanib in Autoimmune Disease-related Interstitial Lung Disease: Real-life Effectiveness, Safety and Tolerance in a Spanish Multicenter Study

    paula pérez garcía1, Miriam Retuerto Guerrero2, yanira chuquimia mendoza3, Jesús Loarce4, Belén Atienza-Mateo5, Carolina Merino6, marina pavia pascual7, cristiana sieiro santos8, Clara Moriano9 and elvira Diez álvarez10, 1Complejo Asistencial Universitario de León, león, Spain, 2Complejo Asistencial Universitario de León, Leon, Spain, 3Complejo asistencial univeritario de león, león, Spain, 4Ramón y Cajal University Hospital, Madrid, Madrid, Spain, 5Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, 6Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda (Madrid), Spain, 7Hospital General Universitario Gregorio Marañon, madrid, Spain, 8Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, 9Hospital León, LEON, Spain, 10Complejo Asistencial Universitario de Leon, Leon

    Background/Purpose: Interstitial lung disease (ILD) is a severe complication of autoimmune diseases (AD). In recent years, new strategies for the treatment of progressive pulmonary fibrosis…
  • Abstract Number: 2059 • ACR Convergence 2024

    The Rs35705950 Promoter Variant of Muc5b Is Associated with Usual Interstitial Pneumonia in Antisynthetase Syndrome

    Daphne Rivero Gallegos1, Mayra Mejía2, Karol J. Nava-Quiroz2, Heidegger N. Mateos-Toledo3, Héctor I. Rocha-González4, Juan C. Huerta-Cruz3, Espiridion Ramos-Martínez5, Gloria Pérez-Rubio3, Ingrid Fricke-Galindo3, Jorge Rojas-Serrano6 and Ramcés Falfán-Valencia3, 1INER, Ciudad de México, Mexico State, Mexico, 2INER, Mexico, Distrito Federal, Mexico, 3INER, Mexico City, Distrito Federal, Mexico, 4Instituto Politècnico Nacional, Mexico City, Distrito Federal, Mexico, 5UNAM, Ciudad de Mexico, Distrito Federal, Mexico, 6National Institute of Respiratory Diseases, Ismael Cosío Villegas, Mexico City, Mexico

    Background/Purpose: Rs35705950 variant in the MUC5B gene promoter is a critical genetic risk factor in idiopathic pulmonary fibrosis (IPF). It has been associated with usual…
  • Abstract Number: 0308 • ACR Convergence 2024

    Interstitial Lung Disease as the First Clinical Manifestation of Connective Tissue Diseases

    Juan A. Meraz-Ostiz, Aina Puiggròs-Ferrer, Núria Bou, Irene Carrión-Barberà, Jordi Monfort, Carolina Pérez-García, Diana Badenes, Eva Balcells and Anna Pros-Simon, Hospital del Mar, Barcelona, Spain

    Background/Purpose: Interstitial lung disease (ILD) is a common complication of connective tissue diseases (CTDs), significantly influencing prognosis and mortality. The prevalence and characteristics of new…
  • Abstract Number: 1169 • ACR Convergence 2024

    Efficacy of Intravenous Immunoglobulin (Octagam 10%) on Pulmonary Manifestations in Patients with Dermatomyositis: Results from the ProDERM Study

    Rohit Aggarwal1, christina Charles-Schoeman2 and Joachim Schessl3, and the ProDERM Investigators, 1Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, 2UCLA Medical Center, Santa Monica, CA, 3Friedrch-Baur-Institut; Ludwig-Maximilians University of Munich, Munich, Germany

    Background/Purpose: Interstitial lung disease (ILD) and other pulmonary manifestations are a major cause of mortality and morbidity in patients with dermatomyositis (DM). The ProDERM study…
  • Abstract Number: 2208 • ACR Convergence 2024

    Clinical, Imaging and Treatment Characteristics of Patients with Progressive Systemic Autoimmune Rheumatic Disease-related Interstitial Lung Diseases (SARD-ILDs) in the ILD-PRO Registry

    Aparna Swaminathan1, Jeremy Weber2, Jamie Todd3, Scott Palmer3, Megan Neely3, Peide Li4 and Ann Chauffe5, and on behalf of the ILD-PRO Registry investigators, 1Duke Clinical Research Institute, Durham, North Carolina, USA; Duke University Medical Center, Durham, North Carolina, USA, Durham, NC, 2Duke Clinical Research Institute, Durham, NC, 3Duke Clinical Research Institute, Durham, North Carolina, USA; Duke University Medical Center, Durham, North Carolina, USA, Durham, 4Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, 5Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, CT

    Background/Purpose: The ILD-PRO Registry is a multicenter US registry of patients with progressive fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF). We…
  • Abstract Number: 0317 • ACR Convergence 2024

    Progressive Fibrosing Intersticial Lung Disease of Autoimmune Origin and Antifibrotic Medication: NEREA Registry

    Pablo Moreno-Fresneda1, Cristina Vadillo-Font2, Fredeswinda Romero-Bueno3, Olga Sánchez-Pernaute4, Rosalía Laporta5, hildegarda Godoy Tundidor6, Belén López-Muñiz7, Laura Cebrián7, Claudia Valenzuela8, Irene Llorente-Cubas9, Jesús Loarce10, Juan Rigual10, Benjamin fernandez-Gutierrez11, M Asuncion Nieto1 and lydia Abasolo Alcazar12, 1Hospital Clínico San Carlos, Madrid, Madrid, Spain, 2Hospital Clinico S Carlos, Madrid, Spain, 3Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain, 4Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain, 5Hospital Universitario Puerta de Hierro, Madrid, Spain, 6Servicio de Reumatología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Madrid, Spain, 7Hospital Universitario Infanta Leonor, Madrid, Spain, 8ILD Unit, Pulmonology Department, Hospital Universitario de la Princesa, University Autonomade Madrid, Madrid, Spain, Madrid, Madrid, Spain, 9Hospital Universitario de La Princesa, Madrid, Spain, 10Ramón y Cajal University Hospital, Madrid, Madrid, Spain, 11HOSPITAL CLINICO SAN CARLOS, Madrid, Spain, 12IdISSC. HCSC, Madrid, Spain

    Background/Purpose: Nintedanib and pirfenidone are approved therapies for the management of patients with progressive fibrosing interstitial lung diseases (ILD), including those of autoimmune origin (ILD…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology